128 related articles for article (PubMed ID: 38761480)
21. Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea.
Chang S; Choi JS; Leem AY; Lee SH; Lee SH; Kim SY; Chung KS; Jung JY; Kang YA; Kim YS; Lee JG; Paik HC; Shim HS; Lee EH; Park MS
Sci Rep; 2022 May; 12(1):8260. PubMed ID: 35585116
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes and survival following lung transplantation in patients with lymphangioleiomyomatosis.
Khawar MU; Yazdani D; Zhu Z; Jandarov R; Dilling DF; Gupta N
J Heart Lung Transplant; 2019 Sep; 38(9):949-955. PubMed ID: 31303421
[TBL] [Abstract][Full Text] [Related]
23. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
[TBL] [Abstract][Full Text] [Related]
24. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis.
Bissler JJ; McCormack FX; Young LR; Elwing JM; Chuck G; Leonard JM; Schmithorst VJ; Laor T; Brody AS; Bean J; Salisbury S; Franz DN
N Engl J Med; 2008 Jan; 358(2):140-51. PubMed ID: 18184959
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
[TBL] [Abstract][Full Text] [Related]
26. Sirolimus Suppresses Phosphorylation of Cofilin and Reduces Interstitial Septal Thickness in Sporadic Lymphangioleiomyomatosis.
Huang YL; Chen PR; Lai YJ; Hsu HH
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445268
[TBL] [Abstract][Full Text] [Related]
27. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
[TBL] [Abstract][Full Text] [Related]
28. Clinical features of 280 hospitalized patients with lymphangioleiomyomatosis in Japan.
Hasegawa W; Yamauchi Y; Yasunaga H; Sunohara M; Jo T; Matsui H; Fushimi K; Takami K; Nagase T
Respirology; 2015 Jan; 20(1):160-5. PubMed ID: 25385157
[TBL] [Abstract][Full Text] [Related]
29. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
[TBL] [Abstract][Full Text] [Related]
30. Long-Term Results of Bilateral Lung Transplantation in Patients With End-Stage Pulmonary Lymphangioleiomyomatosis.
Salman J; Ius F; Sommer W; Siemeni T; Fleissner F; Alhadidi H; Kugler C; Avsar M; Haverich A; Warnecke G; Tudorache I; Kuhn C
Prog Transplant; 2019 Jun; 29(2):115-121. PubMed ID: 31084354
[TBL] [Abstract][Full Text] [Related]
31. mTOR treatment in lymphangioleiomyomatosis: the role of everolimus.
Yates DH
Expert Rev Respir Med; 2016; 10(3):249-60. PubMed ID: 26847859
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis.
Gao N; Zhang T; Ji J; Xu KF; Tian X
Orphanet J Rare Dis; 2018 Aug; 13(1):134. PubMed ID: 30107845
[TBL] [Abstract][Full Text] [Related]
33. The efficacy and safety of pharmacological treatments for lymphangioleiomyomatosis.
Wang Q; Luo M; Xiang B; Chen S; Ji Y
Respir Res; 2020 Feb; 21(1):55. PubMed ID: 32059669
[TBL] [Abstract][Full Text] [Related]
34. Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival.
Tanaka S; Miyoshi K; Higo H; Kurosaki T; Otani S; Sugimoto S; Yamane M; Kiura K; Toyooka S; Oto T
Respir Investig; 2019 Mar; 57(2):165-171. PubMed ID: 30600175
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.
Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Takada T; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Arai T; Sugimoto C; Hattori N; Watanabe K; Tamada T; Akazawa K; Tanaka T; Nakata K
Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1182-1189. PubMed ID: 28752672
[TBL] [Abstract][Full Text] [Related]
36. Elucidation of prognostic factors and the effect of anti-fibrotic therapy on waitlist mortality in lung transplant candidates with idiopathic interstitial pneumonias.
Miyahara S; Waseda R; Tokuishi K; Sato T; Iwasaki A; Shiraishi T
Respir Investig; 2021 Jul; 59(4):428-435. PubMed ID: 33888448
[TBL] [Abstract][Full Text] [Related]
37. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment.
Morton JM; McLean C; Booth SS; Snell GI; Whitford HM
J Heart Lung Transplant; 2008 Apr; 27(4):462-5. PubMed ID: 18374885
[TBL] [Abstract][Full Text] [Related]
38. Rates of change in FEV
Taveira-DaSilva AM; Julien-Williams P; Jones AM; Stylianou M; Moss J
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519926
[TBL] [Abstract][Full Text] [Related]
39. Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex.
Ebrahimi-Fakhari D; Agricola KD; Tudor C; Krueger D; Franz DN
Pediatr Neurol; 2020 Apr; 105():59-61. PubMed ID: 31924480
[TBL] [Abstract][Full Text] [Related]
40. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
Johnson J; Somerfield W; Johnson SR
Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
